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CREATING A MODEL ANTIGEN SYSTEM TO 
TEST THE MECHANISM OF GCC-SPECIFIC 
TOLERANCE 
 
 
 
 
o Patrick Ihejirika 
 
Cancer Cases and Deaths 
Colorectal Cancer  
 
 
 
o The main treatment options include: 
          Surgery, chemo-, radiation, biological therapy. 
       All treatments present a risk of side effects 
 
o Current standard of care: FOLFOX, FOLFIRI, etc 
 Developed in 1980 
 Minimal response rate 
 Prognosis: 5 year survival rate of 63% 
 
Failure is due to the lack of molecularly 
defined tumor-associated antigens that 
can be reliably considered:  
•Tumor-specific 
•Sufficiently immunogenic  
•Shared among different patients 
Adapted from: Dalerba P, et al. Crit Rev Oncol Hemat 2003;46(1):33-57. 
Colorectal Cancer Immunotherapy 
Meta-analysis of clinical trials reveal a 
very weak clinical response rate (<1%) 
for active specific immunotherapy 
procedures currently available for 
colorectal cancer 
Nagorsen D, et al.  Clin Cancer Res 2006;12:3064-9. 
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Mucosa-Restricted GCC Expression 
E Lin et al, unpublished data Swensen et al. 1996. Biochemical and Biophysical 
Research Communications, 225: 1009-1014 
S Schulz et al, unpublished data 
Human Colon 
Adapted from Carrithers, et al (1996) Dis Colon Rectum 39:131 
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Anti-Tumor Immunity 
GCC-Specific Immune Responses 
A. Snook et al. JNCI 2008; 100(13):950-961 
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Predicted CD4 Tolerance Mechanism  
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Epitopes and surface 
expression 
Creating GCC-based model antigen 
Steps: 
o cloning different epitopes and signal sequences into GCC: 
 Bip  and Prp 
 
o clone the constructs into mammalian expression plasmid 
(retrovirus) 
 
o create cell lines expressing the constructs by infecting them with 
retrovirus containing our constructs 
 
o test the new cell lines for 1) Chimeric antigen expression, 2) 
Chimeric antigen subcellular location, 3) epitope presentation 
 
o work with Dr Eisenlohr’s lab to see how different signal 
sequences and model epitopes affect our new model antigen. 
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Cutting inserts out 
o Sequenced pENTR clones 
o Cut inserts out with NotI and SalI 
o Cut pMSCV-Puro with NotI and SalI 
o Ligated inserts with pMSCV-Puro 
o Transformed bacteria 
o Screened colonies 
 
Results 
Bip 1 2 3 4 5 6 7 
8 9 10 11 - + 
Prp 
Summary/Future Goal 
o Create stable cell lines expressing the constructs 
by target cell lines with retrovirus containing our 
constructs. 
o Test the new cell lines for 1) chimeric antigen 
expression, 2) define the subcellular location or 
our antigen, 3) quantify epitope presentation 
o Work with Dr. Eisenlohr’s lab to see how different 
signal sequences and model epitopes affect our 
new model antigen. 
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